Long Jiang

Publications
CV
Public outreach and news

Articles

Article: MOLECULAR ONCOLOGY. 2024;18(2):317-335

High-content screening of drug combinations of an mPGES-1 inhibitor in multicellular tumor spheroids leads to mechanistic insights into neuroblastoma chemoresistance.

Zaghmi A; Aybay E; Jiang L; Shang M; Steinmetz-Späh J; Wermeling F; Kogner P; Korotkova M; Östling P; Jakobsson P-J; Seashore-Ludlow B; Larsson K
Article: SCIENTIFIC REPORTS. 2023;13(1):4583

MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia.

Lerma Clavero A; Boqvist PL; Ingelshed K; Bosdotter C; Sedimbi S; Jiang L; Wermeling F; Vojtesek B; Lane DP; Kannan P
Article: CANCER RESEARCH COMMUNICATIONS. 2022;2(9):1075-1088

The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy.

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Article: ONCOSCIENCE. 2022;9:27-29

A CRISPR-p53 interactome with potential implications for clinical CRISPR/Cas9 use.

Jiang L; Wermeling F
Article: CANCER RESEARCH. 2022;82(1):36-45

CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies.

Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Article: COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL. 2021;19:5360-5370

A rapid CRISPR competitive assay for in vitro and in vivo discovery of potential drug targets affecting the hematopoietic system.

Shen Y; Jiang L; Iyer VS; Raposo B; Dubnovitsky A; Boddul SV; Kasza Z; Wermeling F
Journal article: CANCER IMMUNOLOGY RESEARCH. 2020;8(3_Supplement):a79

Abstract A79: Inhibition of p53-MDM2 protein interaction reduces tumor growth in a mouse melanoma model

Ingelshed K; Lianoudaki D; Lama D; Sohn S; Fritz N; Jiang L; Wermeling F; Karlsson M; Lane DP; Sedimbi SK
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2020;117(6):3103-3113

IL-4 controls activated neutrophil FcγR2b expression and migration into inflamed joints.

Panda SK; Wigerblad G; Jiang L; Jiménez-Andrade Y; Iyer VS; Shen Y; Boddul SV; Guerreiro-Cacais AO; Raposo B; Kasza Z; Wermeling F
Article: CELL REPORTS. 2019;29(5):1074-1081.e5

Neutrophil Recruitment to Noninvasive MRSA at the Stratum Corneum of Human Skin Mediates Transient Colonization.

Schulz A; Jiang L; de Vor L; Ehrström M; Wermeling F; Eidsmo L; Melican K
Article: BIOINFORMATICS. 2017;33(7):1099-1100

Green listed-a CRISPR screen tool.

Panda SK; Boddul SV; Jiménez-Andrade GY; Jiang L; Kasza Z; Fernandez-Ricaud L; Wermeling F
Article: SCIENTIFIC REPORTS. 2017;7(1):354

A Novel Method of Evaluating Knee Joint Stability of Patients with Knee Osteoarthritis: Multiscale Entropy Analysis with A Knee-Aiming Task.

Zhou D; Zhang S; Zhang H; Jiang L; Zhang J; Fang J
Article: BEIJING DA XUE XUE BAO. 2016;48(2):257-262

[Evaluation of physical function for the end-stage osteoarthritis patient waiting for the total knee replacement].

Li ZC; Jiang L; Zhang S; Qin XY; White Pt DK; Hou YF; Zhou ZW; Lin JH

All other publications

Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S6 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Supplementary Data from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S8 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S7 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Data from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Data from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S5 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Table S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S5 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S3 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Supplementary Data from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S3 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Table S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S2 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S4 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S6 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S2 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S7 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S9 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S4 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S8 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Figure S9 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies

Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies

Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies

Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies

Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies

Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies

Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies

Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies

Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Supplementary Figure from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies

Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies

Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Supplementary Figure from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies

Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies

Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Preprint: BIORXIV. 2022

MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia

Clavero AL; Boqvist PL; Ingelshed K; Bosdotter C; Sedimbi S; Jiang L; Wermeling F; Vojtesek B; Lane DP; Kannan P
Thesis / dissertation: 2022

CRISPR-based drug target discovery : implications for CRISPR-based therapies

Jiang, Long
Preprint: BIORXIV. 2021

CRISPR enriches for cells with mutations in a p53-related interactome, and this can be inhibited

Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Preprint: BIORXIV. 2021

A rapid CRISPR competitive assay for in vitro and in vivo discovery of potential drug targets affecting the hematopoietic system

Shen Y; Jiang L; Iyer VS; Raposo B; Boddul S; Kasza Z; Wermeling F
Conference publication: EUROPEAN JOURNAL OF IMMUNOLOGY. 2021;51:397

A rapid CRISPR competitive assay for in vitro and in vivo discovery of potential drug targets affecting the hematopoietic system

Shen Y; Jiang L; Iyer VS; Raposo B; Boddul SV; Kasza Z; Wermeling F
Review: COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL. 2020;18:2237-2246

Designing custom CRISPR libraries for hypothesis-driven drug target discovery.

Iyer VS; Jiang L; Shen Y; Boddul SV; Panda SK; Kasza Z; Schmierer B; Wermeling F
Conference publication: CANCER IMMUNOLOGY RESEARCH. 2020;8(3):71

Inhibition of p53-MDM2 protein interaction reduces tumor growth in a mouse melanoma model.

Ingelshed K; Lianoudaki D; Lama D; Sohn S; Fritz N; Jiang L; Wermeling F; Karlsson M; Lane DP; Sedimbi SK
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):276

Deciphering the IL-4Rα regulating factor, produced during inflammation, by customized CRISPR screens

Panda SK; Kasza Z; Boddul S; Jimenez Y; Jiang L; Wigerblad G; Fernandez-Ricaud L; Wermeling F
Meeting abstract: OSTEOARTHRITIS AND CARTILAGE. 2015;23:a162

DISTINCT EXPRESSION OF SREBP-2 IN NORMAL AND OSTEOARTHRITIC CHONDROCYTES

Tao KS; Tang X; Wang B; Li JR; Jiang L; Lin HJ
Meeting abstract: OSTEOARTHRITIS AND CARTILAGE. 2015;23:a397-a398

DO PHYSICIANS TREAT OSTEOARTHRITIS PROPERLY IN CHINA: ANALYSIS OF 67382 OUT-PATIENTS FROM PEKING UNIVERSITY PEOPLE'S HOSPITAL

Zhang H; Jiang L; Li Z; Dong X; Zhong Q; Lin J
Meeting abstract: OSTEOARTHRITIS AND CARTILAGE. 2015;23:a373

THE EFFECT OF EDUCATION FOR DAILY PHYSICAL ACTIVITY LEVEL RECOVERY OF OSTEOARTHRITIS PATIENTS AFTER TOTAL KNEE ARTHROPLASTY. A PROSPECTIVE RANDOMIZED CONTROLLED CLINICAL TRIAL USING ACCELEROMETRY

Li Z; Jiang L; Lin J
Meeting abstract: OSTEOARTHRITIS AND CARTILAGE. 2015;23:a368

THE OBJECTIVE EVALUATION OF DAILY PHYSICAL ACTIVITY FOR KNEE OSTEOARTHRITIS PATIENTS AFTER TOTAL KNEE ARTHROPLASTY. A PROSPECTIVE CLINICAL TRIAL USING ACCELEROMETRY

Jiang L; Li Z; Lin J
Meeting abstract: OSTEOARTHRITIS AND CARTILAGE. 2015;23:a203

THE ANALYSIS OF ECONOMIC BURDEN FOR THE TREATMENT OF OSTEOARTHRITIS IN CHINA: ANALYSIS OF 67382 OUT-PATIENTS FROM PEKING UNIVERSITY PEOPLE'S HOSPITAL

Zhang H; Li Z; Jiang L; Dong X; Zhong Q; Lin J
Meeting abstract: OSTEOARTHRITIS AND CARTILAGE. 2014;22:s126

A NEW METHOD TO EVALUATE THE PROPRIOCEPTION IN KNEE OSTEOARTHRITIS: MULTISCALE ENTROPY

Jiang L; Zhang H; Zhou D; Lin J; Zhang J
Show more

Employments

Postdoctoral Studies, Department of Clinical Neuroscience, Karolinska Institutet, 2022-2025

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Medicine, Solna, Karolinska Institutet, 2022

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI